SAM
SPRY icon

Smartleaf Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Smartleaf Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7K Hold
1,952
– – ﹤0.01% 2108
2026
Q1 		$15.3K Hold
1,952
– – ﹤0.01% 2101
2025
Q4 		$22.7K Buy
1,952
+1,400
+254% +$13.6K ﹤0.01% 1959
2025
Q3 		$5.37K Buy
+552
New +$7.92K ﹤0.01% 2355

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Smartleaf Asset Management's SPRY Position: Q2 2026 in Review

Smartleaf Asset Management held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 1,952 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2108.

Smartleaf Asset Management first reported a position in SPRY in Q3 2025 and has held it in 4 quarters since. The position peaked at $22.7K in Q4 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Smartleaf Asset Management held 1,952 shares of ARS Pharmaceuticals worth $16.7K as of Q2 2026.
  • Smartleaf Asset Management left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2108 holding.
  • Smartleaf Asset Management first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Smartleaf Asset Management's ARS Pharmaceuticals position peaked at $22.7K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.